Cell Therapy Insights: Translation and Production
Meet and network with experts in cell therapy translation and production
Miltenyi Biotec and BioInnovation Institute (BII) are pleased to announce Cell Therapy seminar series featuring leading cell therapy entrepreneurs and innovators. The series consists of three events at the BioInnovation Institute in Copenhagen:
- Stem Cell Therapy (May 31)
- Immuno-oncology (September 27)
- Cell Therapy Translation and Production (November 10)
We welcome you to the third networking and seminar session on Translation and Production of cell therapies on November 10, 2022.
We have invited Anna Pasetto, Director of Center for Advanced Cell Therapy (ACT) at Oslo University Hospital. Anna has previously worked as Assistant Professor at Karolinska Institute (KI), and has solid experience from translating cell therapies through her assignment as Managing Director at the pre-GMP facility at KI. Anna recently moved to Oslo and ACT which will be handling pre-GMP services (scale-up, GMP transfer, GMP advice for ATMPs, regulatory support etc.) as well as GMP services (Cell isolation, cell expansion, vector production, purification, transduction etc.)
Furthermore we have invited Jan Talts, Chief Operating Officer at Amniotics AB. Amniotics was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Hospital, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). In 2020 they also completed and process validated a GMP manufacturing facility in their own facilities in Lund.
Xintela AB was founded in 2009, based on many years of research at Lund University. In 2013, Xintela initiated its research and development operations with a focus on developing stem cell products for the repair of damaged cartilage, and since then the company has managed to build their own GMP facility with a license to produce ATMP´ s. This year Xintela also started its first clinical study with the stem cell product XSTEM in patients with knee osteoarthritis. We are pleased to welcome Christel Reuterswärd (Head of Manufacturing) and Tina Uvebrant (Head of Stem Cell Research) to present the exciting journey from a small R&D company to a fully capable GMP manufacturing site.
After the presentations there will be a Q&A session where you can ask your questions to the experts, followed by a networking session with gourmet finger food in BII´s new social event space.
15:30 – Meet and greet, refreshments and networking
16:00 – Markus Herrgård, Chief Technology Officer, BioInnovation Institute/Martin Schalén, Biopharma Account Manager Miltenyi Biotec Nordics – Welcome and introduction
16:05 – Jan Talts, Chief Operating Officer, Amniotics AB
– Amniotics voyage – taking an ATMP from idea, through GMP, to clinic
16:30 – Anna Pasetto, Director of Center for Advanced Cell Therapy (ACT), Oslo University Hospital
– A new support infrastructure for the early steps of cell therapy development
16:55: Christel Reuterswärd, Head of Manufacturing/ Tina Uvebrant, Head of Stem Cell Research, Xintela AB
– XSTEM: from discovery to clinical studies
17.20 – Q&A roundtable discussion
17.40 – Drinks, refreshments, networking etc.